RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG THERAPEUTIC POSITIONING REPORT EVALUATORS FROM THE SPANISH AGENCY OF MEDICINES
Author(s)
Hernández C1, Blázquez A1, Gil A2, Badia X2
1Spanish Agency of Medicinal Products and Medical Devices (AEMPS), Madrid, Spain, 2Omakase Consulting, Barcelona, Spain
OBJECTIVES: To assess the value of applying reflective MCDA to the generation of drug Therapeutic Positioning Reports (TPR) in Spain. METHODS: TRP are evaluation reports performed by the AEMPS to support P&R in Spain. AEMPS healthcare professionals involved in the generation of TPR participated in two MCDA sessions using the EVIDEM (v 4.0) framework. TPR currently considers the assessment of “comparative effectiveness”, “safety”, “criteria of use” and “follow-up” for the drug under assessment. In each session, the EVIDEM criteria were presented and weighted using a direct rating scale (1: low relative importance; 5: high relative importance). An example of the assessment of a biological drug in psoriasis was used to rate the evidence matrix and numbers were used to establish a reflective discussion among participants. RESULTS: A total of
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PHP270
Topic
Health Technology Assessment, Organizational Practices
Topic Subcategory
Academic & Educational, Decision & Deliberative Processes
Disease
Multiple Diseases
Your browser is out-of-date
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now